Skip to main content

Table 2 Median percent change in biomarker levels from baseline by ACR-Pedi-30 responder status

From: The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

  Placebo +MTX Infliximab 3 mg/kg +MTX
  ACR-Pedi-30 Responder ACR-Pedi-30 Nonresponder P-value ACR-Pedi-30 Responder ACR-Pedi-30 Nonresponder P-value
Biomarker N Median N Median   N Median N Median  
Week 2
   CRP 29 -11.1 28 0.0 NS 39 -54.3 19 0.0 NS
   ICAM-1 13 -10.6 18 4.2 NS 21 -24.5 9 -3.8 0.0105
   IL-12p40 16 -16.6 16 -16.2 NS 20 -9.8 9 -5.0 NS
   IL-6 12 -49.6 12 6.8 0.0334 17 -57.1 9 -66.1 NS
   MMP-3 11 -0.6 16 -0.8 NS 21 -60.3 9 -4.8 0.0253
   TNF-α 16 0.0 18 0.0 NS 24 0.0 9 0.0 NS
   VEGF 12 4.6 18 -5.6 NS 22 -10.6 8 -2.5 NS
Week 14
   CRP 29 -40.0 27 -6.3 NS 39 -55.0 19 0.0 0.0011
   ICAM-1 13 -8.0 18 12.4 NS 22 -21.7 8 4.8 0.0304
   IL-12p40 15 -19.4 17 -18.5 NS 21 -4.0 9 10.8 NS
   IL-6 11 -16.2 14 -20.6 NS 18 -62.6 8 -26.5 NS
   MMP-3 11 21.7 17 -21.7 NS 22 -55.5 8 8.2 0.0091
   TNF-α 16 -4.8 18 0.0 NS 24 0.0 9 0.0 NS
   VEGF 11 13.2 18 -6.7 NS 23 -18.9 7 18.7 NS
  1. ACR-Pedi-30, American College of Rheumatology Pediatric 30 Definition of Improvement; MTX, methotrexate; NS, non-significant; CRP, C-reactive protein; IL-6, interleukin-6; MMP-3, matrix metalloproteinase-3; ICAM-1, intracellular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; IL-12p40, interleukin 12; TNF-α, tumor necrosis factor-α.